BioCryst Pharmaceuticals BCRX Enterprise value

Enterprise value at other companies

Ionis PharmaceuticalsIONS

$13.02B+91.2%

BridgeBio PharmaBBIO

$16.77B+178%

Agios PharmaceuticalsAGIO

$2.14B+12.4%

PrecigenPGEN

$1.46B+234%

Ultragenyx PharmaceuticalRARE

$1.83B-51.1%

AnaptysBio, Inc.ANAB

$1.35B+176%

FAQ

What is BioCryst Pharmaceuticals's enterprise value?

BioCryst Pharmaceuticals (BCRX) reported enterprise value of $2.8B in Q2 2026.

How has BioCryst Pharmaceuticals's enterprise value changed year-over-year?

BioCryst Pharmaceuticals's enterprise value increased by 24.6% year-over-year, from $2.24B to $2.8B.

What is the long-term trend for BioCryst Pharmaceuticals's enterprise value?

Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's enterprise value has grown at a 5.5% compound annual growth rate (CAGR), from $1.2B to $1.57B.

What does enterprise value mean?

Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.